It informs drug development strategies so that they are more clearly aligned to healthcare needs
It reduces uncertainty in predicting the use/outcomes and costs of introducing new health technologies
It is increasingly enabling a learning healthcare environment where quality and efficiencies can be more easily assessed and new pricing and incentive models are made possible
I have no doubt that the potential of RWE can only be realised through collaboration – many parties working together to create a more evidenced-based, complete pictures of the patient experience. Just today AstraZeneca announced a memorandum of understanding with the Health and Social Care Information Centre (HSCIC) to improve the usefulness of real-world data in healthcare decision making and better understand the role medicines play in helping patients with chronic diseases in England.
Together AstraZeneca and the HSCIC will develop important capabilities for linking disparate sources of real-world health information from the National Health Service for healthcare decision-making and business intelligence purposes, while adhering to strict information governance principles ensuring patient confidentiality. This collaboration is the first of its kind between a pharmaceutical company and the HSCIC, England’s central, authoritative source of health and social care information, and will support the wider U.K. Government Life Sciences strategy and Growth Agenda.